ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Scheme : Project Grants
Research Topic : interactions
Clear All
Filter by Field of Research
Structural Biology (incl. Macromolecular Modelling) (5)
Signal Transduction (4)
Biochemistry and Cell Biology not elsewhere classified (3)
Medical Bacteriology (3)
Medical Virology (3)
Pharmacology and Pharmaceutical Sciences not elsewhere classified (3)
Biologically Active Molecules (2)
Cellular Interactions (incl. Adhesion, Matrix, Cell Wall) (2)
Protein Trafficking (2)
Autoimmunity (1)
Cancer Cell Biology (1)
Central Nervous System (1)
Developmental Genetics (incl. Sex Determination) (1)
Enzymes (1)
Gastroenterology and Hepatology (1)
Haematology (1)
Molecular Targets (1)
Neurology and Neuromuscular Diseases (1)
Vision Science (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (37)
Filter by Status
Closed (37)
Filter by Scheme
Project Grants (37)
Filter by Country
Australia (4)
Filter by Australian State/Territory
VIC (2)
QLD (1)
SA (1)
WA (1)
  • Researchers (0)
  • Funded Activities (37)
  • Organisations (77)
  • Funded Activity

    The Pharmacology Of Sulfotransferase 4A1

    Funder
    National Health and Medical Research Council
    Funding Amount
    $576,966.00
    Summary
    SULT4A1 is not a sulfotransferase, but a sulfotransferase inhibitor. It forms high affinity heterodimers with other sulfotransferases via a conserved dimerisation site in its carboxyl terminus attenuating catalytic activity. Consequently, it is important for the metabolism of numerous important molecules including estrogens, thyroid hormones, neurotransmitters and many therapeutic agents.
    More information
    Funded Activity

    Dynamics And Mechanisms Of Immune Complex-mediated Skin Inflammation

    Funder
    National Health and Medical Research Council
    Funding Amount
    $526,467.00
    Summary
    Type III hypersensitivity underlies a number of common autoimmune diseases, including rheumatoid arthritis and lupus erythematosus. These diseases are caused by the deposition of immune complexes (IC) and the accumulation of neutrophils within small blood vessels. We will use real time imaging to dissect in space and time the recruitment of neutrophils and IC deposition during type III hypersensitivity reactions in order to better understand the pathogenesis of these conditions.
    More information
    Funded Activity

    Location, Location, Location: Sub-cellular Specific Targeting Of JNK As A Novel Therapy In Breast Cancer.

    Funder
    National Health and Medical Research Council
    Funding Amount
    $633,755.00
    Summary
    The ‘triple negative’ breast cancer subtype is the most aggressive form of breast cancer, and unlike other subtypes, there are no drugs to specifically this subtype. While many potential drug targets have been identified, they cannot be utilised clinically because of other beneficial roles within the body. We are now deploying our innovative experimental platforms to specifically target the tumour promoting functions of a protein known as ‘JNK’, whilst retaining its beneficial functions.
    More information
    Funded Activity

    Diabolic Regulation Of Macrophage Cell Death Pathways By Legionella

    Funder
    National Health and Medical Research Council
    Funding Amount
    $616,912.00
    Summary
    The bacterial pathogen Legionella causes fatal pneumonia in immuno-compromised humans. Infections depend on a sophisticated secretion machinery that translocates hundreds of proteins into host cells. These proteins subvert several essential defense pathways, including cell death signals. This project will highlight how Legionella interfere with cell death pathways and control the survival of its host cells. These findings will facilitate the development of promising new anti-bacterial agents.
    More information
    Funded Activity

    Novel Antagonists Of The Nuclear Receptor LRH-1

    Funder
    National Health and Medical Research Council
    Funding Amount
    $762,292.00
    Summary
    LRH-1 is a protein that is inappropriately present in cancers of the breast and other tissues. It causes cancer cells to divide and multiply, and therefore it is important to block its activity. There are, however, no treatments available that block LRH-1. This proposal brings together a team of researchers with broad experience. We will use high throughput technologies to identify and characterize novel LRH-1 inhibitors, and demonstrate their efficacy in reducing the growth of cancer cells.
    More information
    Funded Activity

    Amyloid Precursor Protein Signalosome: Directing Abeta Production In Alzheimer's Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $681,459.00
    Summary
    Alzheimer's disease is the most common form of dementia and is the fourth biggest killer in developed countries. Amyloid precursor protein plays a central role in the development of the disease, through the generation of a toxic peptide called Abeta. In this project we will decipher the fine molecular details of what the protein looks like and how various molecules known to bind to it affect Abeta production. This knowledge is expected to lead to novel therapies to treat the disease.
    More information
    Funded Activity

    The Human Eukaryotic Translation Elongation Factor 1A Is A Paramyxovirus Virus Dependency Factor

    Funder
    National Health and Medical Research Council
    Funding Amount
    $585,497.00
    Summary
    Several paramyxoviruses cause respiratory disease in infants, young children and the elderly worldwide. Another paramyxovirus that can be contracted by people from infected horses, Hendra virus, is often fatal. There are currently no vaccines against these viruses, and treatment is generally limited to relief of symptoms. In this project we will uncover how these viruses use human proteins for their growth inside cells, with an aim to develop novel therapeutic strategies.
    More information
    Funded Activity

    Modulating Cellular Copper Levels To Prevent The Effects Of Excitotoxicity In Neurodegenerative Diseases

    Funder
    National Health and Medical Research Council
    Funding Amount
    $434,652.00
    Summary
    Exitotoxicity has been implicated in many neurological disorders incluing Alzheimer's and Huntington's disesaes. This toxicity can be inhibited by modulated intracellular copper levels. Here we will ascertain the therapeutic potential of strategies designed to increase cellular copper levels.
    More information
    Funded Activity

    Host Metabolism And Responses Contributing To Flavivirus Replication And Pathogenesis

    Funder
    National Health and Medical Research Council
    Funding Amount
    $592,772.00
    Summary
    We aim to determine how viruses affect the cells they infect, In particular how they can alter the metabolism and balance of lipids in cells and how this impacts the bodies capability to respond immunologically. We believe that by understanding these basic principles we can target ares fr antiviral therapeutic potential.
    More information
    Funded Activity

    Function And Molecular Mechanism Of Histidine-rich Glycoprotein In Necrotic Cell And Pathogen Clearance

    Funder
    National Health and Medical Research Council
    Funding Amount
    $525,957.00
    Summary
    This research proposal is to investigate the molecular mechanism and function of a blood serum protein, histidine-rich glycoprotein (HRG), in protecting against tissue injury caused by inflammation and infection. HRG has been implicated in controlling important aspects of tissue injury by aiding removal of dead cells and pathogens. Understanding the role of HRG in these disease settings may allow the development of approaches for the treatment of inflammatory, autoimmune and infectious disease.
    More information

    Showing 1-10 of 37 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback